Background {#Sec1}
==========

Since 2011, when the US Food and Drug Administration (FDA) approved ipilimumab for advanced melanoma, there has been an explosion of research interest and drug development for harnessing the immune system to fight against cancer. A general search for "immune therapy and cancer" in the clinicaltrials.gov database from 2000 to 2010 shows 640 hits, while the same search on March 20, 2015 shows 7815 hits and December 23, 2015 shows 8941 hits. Active research in tumor immunology includes studies on adoptive T cell therapy and cancer vaccine, as well as clinical investigations into immune checkpoint blockade in monotherapy or combination therapies. First generation programed cell-death protein 1 (PD-1) blockade antibodies pembrolizumab and nivolumab obtained US FDA approval for advanced melanoma in 2014 and as second line therapy for non-small cell lung cancer (NSCLC) in 2015. We have seen a surge in the availability of immune checkpoint inhibitors for multiple cancer indications. Forecasts for 2013--2020 project that the market for immunotherapy will increase from approximately \$1 billion (US dollars) in 2013 to in excess of \$7 billion in 2020 (corresponding to 33 % annual growth), across the seven major markets (USA, France, Germany, Italy, Spain, UK, and Japan) \[[@CR1]\].

Unlike chemotherapy and molecularly targeted therapy, the checkpoint blockade immunotherapies result in durable clinical responses through the induction, activation, and expansion of tumor-specific cytotoxic T cells. Immune checkpoints play an essential role in maintaining self-tolerance and regulating the amplitude and duration of T cell responses. Two cytotoxic T cell immune checkpoint receptors (cytotoxic T-lymphocyte antigen 4 (CTLA-4) and PD-1) deliver inhibitory signals when bound to their respective ligands CD80/86 and programed cell-death ligand 1 (PD-L1)/2. Immunotherapies with checkpoint blockade antibodies that block CTLA-4 and PD-1 (or its ligand PD-L1) can restore and augment cytotoxic T cell responses against chemotherapy-refractory tumors, leading to durable responses and prolonged overall survival with tolerable toxicity. In the lymphatic tissues, anti-CTLA-4 antibody induces non-tumor-specific immune activation that is largely de novo induction of new responses. In tumor microenvironment, anti-PD-1/PD-L1 antibody targets tumor-induced immune defects and repairing ongoing tumor immunity. In addition to these anti-CTLA-4 and anti-PD-1/PD-L1 antibodies, drugs targeting other immune checkpoints and/or co-stimulatory ligand-receptor inhibitors, such as lymphocyte activation gene 3 protein (LAG3) and T cell immunoglobulin and mucin-domain containing protein 3 (TIM-3), are currently being explored in many tumor types and will be discussed further in the "[Principles of cancer immunotherapy](#Sec2){ref-type="sec"}" section.

Given the distinct and novel mechanisms of action of immunotherapy on effector immune cells, rather than tumor cells, there are emerging tumor response patterns that are not accurately assessed by Response Evaluation Criteria in Solid Tumors (RECIST). In 2009, a guideline for immune-related response criteria (irRC) was proposed for patients with advanced melanoma receiving ipilimumab \[[@CR2]\]. This guideline has been used to evaluate the tumor response for ongoing immune checkpoint blockade therapies \[[@CR3]\]. When assessed appropriately, approximately 20 % of advanced NSCLC patients and 30--40 % of advanced melanoma patients have objective tumor responses to PD-1 blockade monotherapy. The combination of anti-PD-1 and anti-CTLA-4 antibodies increased the clinical response in advanced melanoma patients with a recent FDA approval \[[@CR4]\]. In an attempt to increase the therapeutic, in checkpoint inhibitors, a companion diagnostic of PD-L1 immunohistochemistry (IHC) had been approved by the US FDA for selecting NSCLC patients treated with pembrolizumab. Interestingly, overall tumor responses, progression-free survival (PFS) and overall survival (OS) were not consistently associated with PD-L1 expression in the patients receiving immune checkpoint inhibitors \[[@CR5]\]. In this age of personalized medicine, finding and validating better immune biomarkers will enable us to select patients for cancer immunotherapies. It will also lead to a better understanding of the unique mechanisms of tumor response and resistance, to allow for the development of strategies to improve clinical efficacy, and to lead to better evaluation of response and monitoring assays for host immune function. Validating potential immune biomarkers will enable us to better select patients for cancer immunotherapies and to avoid immune-related adverse effects (irAEs). Many excellent review articles on cancer biomarkers and immune checkpoint inhibitors have been recently published \[[@CR6]--[@CR12]\]. In this review, we will focus on the current knowledge, clinical efficacy, available monitoring assays, and emerging novel technologies for identifying translational biomarkers for immune checkpoint blockade immunotherapies in advanced solid tumors.

Principles of cancer immunotherapy {#Sec2}
==================================

Clinically apparent cancer can be thought of as a host's inability to eliminate transformed cells. Cancer immunotherapy refers to a diverse range of therapeutic approaches that harness the immune system to induce or restore the capacity of cytotoxic T cells, and other immune effector cells, and to recognize and eliminate cancer \[[@CR13], [@CR14]\]. The field of cancer immunotherapy is undergoing a renaissance due to a greater understanding of the immune system and immunosurveillance. The immune system protects the host against tumor development but also promotes tumor growth by selecting for tumors of lower immunogenicity. This dual effect of the immune system on developing tumors creates a dynamic process termed *cancer immunoediting*, which is comprised of three phases: elimination, equilibrium, and escape \[[@CR15]\]. Cancer cells are immunogenic through the generation of tumor-specific mutant antigens (TSMA, neoantigens) from somatic gene structural and/or epigenetic alterations \[[@CR16]\]. During the *elimination phase*, immune effector cells (mainly T and natural killer (NK) lymphocytes) are activated by the inflammatory cytokines released by the growing tumor cells, macrophages, and stromal cells surrounding the tumor cells. The recruited tumor-infiltrating NK cells and macrophages produce interleukin 2 (IL-2), interleukin 12 (IL-12), and interferon gamma (IFNγ), which kill tumor cells by cytotoxic mechanisms such as perforin, tumor necrosis factors (TNF)-related apoptosis-inducing ligands (TRAILs), and reactive oxygen species. Due to heterogeneity, tumor cells with a less immunogenic phenotype are able to escape this elimination phase (i.e., immunosurveillance) and expand during the *equilibrium phase*. The equilibrium phase may occur over a period of many years when, under Darwinian selection, new tumor cell variants emerge with mutations that further increase overall resistance to immune attack. During the *escape phase*, tumor cell variants breach the host's immune defenses conferring further resistance to immune detection \[[@CR17]\].

Major mechanisms for *escape* include defective antigen presentation, tumor-induced inhibitory checkpoint pathways against effector T cell activity, infiltrating immunosuppressive immune cells including regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSCs), and secretion of immunosuppressive cytokines (transforming growth factor beta (TGF-β), IL-6, vascular endothelial growth factor (VEGF)) \[[@CR7], [@CR18], [@CR19]\]. Full activation of T and NK lymphocytes requires the coordinated participation of several surface receptors that meet their cognate ligands through structured transient cell-to-cell interactions known as immune synapses. Current PD-1/PD-L1 blockade therapies aim to boost the patient's effector T cells to specifically recognize and kill cancer cells. Table [1](#Tab1){ref-type="table"} summarizes the current list of major immune checkpoint inhibitors that have obtained FDA approval or are in the late phases of clinical development.Table 1Summary of clinical indication and ongoing evaluation of immune checkpoint inhibitors in major cancer typesTargetDrugClassCompanyClinical indication and ongoing evaluation (status; approval date; trial identifier; country)CTLA-4Ipilimumab (Yervoy®, MDX-010, MDX-101)Human IgG1/kappaBristol-Myers Squibb*Metastatic melanoma* (US FDA approved on March 25, 2011); *metastatic NSCLC* (phase I has been completed; NCT01165216; Japan; phase II reported, NCT00527735, USA; phase III ongoing, NCT01285609; USA; phase III ongoing NCT02279732; China)Tremelimumab (ticilimumab, CP-675206)Human anti-CTLA-4 IgG2 mabMedImmune/AstraZeneca*Metastatic melanoma* (phase I has been completed; NCT01103635; USA; phase II has been completed, NCT00471887, USA); *advanced hepatocellular carcinoma* (phase II has been completed; NCT01008358; Spain); *Metastatic NSCLC* (phase Ib has been reported, NCT02000947, USA; phase II has been reported, NCT02179671, USA; first line, phase III MYSTIC ongoing; NCT02453282; USA)PD-1Nivolumab (Opdivo®, ONO-4538, MDX-1106, BMS-936558)Human IgG4/kappaBristol-Myers Squibb; Ono Pharmaceuticals*Metastatic melanoma* (Japan approval on July 4, 2014; US FDA accelerated approval on December 22, 2014; US FDA approval of nivolumab in combination with ipilimumab for BRAF V600 wild-type tumor on September 30, 2015); *Squamous NSCLC* (US FDA approval on March 4, 2015; European Commission on July 20, 2015); expands to *non-squamous NSCLC* (US FDA approval on October 9, 2015); *advanced (metastatic) renal cell carcinoma* (US FDA approval on November 23, 2015); classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin (US FDA approval on May 17, 2016)Pembrolizumab (Keytruda®, lambrolizumab, MK-3475)Humanized IgG4Merck & Co.*Metastatic melanoma* (USA accelerated approval on September 4, 2014 for patients with disease progression after ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; US FDA expanded to initial treatment on December 18, 2015); *metastatic NSCLC* whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy (US FDA approval on October 2, 2015)Pidilizumab (CT-011)Humanized IgG1CureTech Ltd*Diffuse large-B cell lymphoma* (phase II has been completed; NCT00532259; USA); *metastatic melanoma* (phase II has been completed; NCT01435369; USA)AMP-514 (MEDI0680)Humanized IgG4MedImmune*Advanced malignancies* (phase II is currently recruiting participants; NCT02013804; USA)AUNP-12Peptide antagonistAurigene, Pierre Fabre*Cancer* (preclinical phase, Aurigene granted Pierre Fabre worldwide rights to develop AUNP12 for cancer indications; announced on February 11, 2014; India)PD-L1BMS936559 (MDX-1105)Human IgG4Bristol-Myers Squibb*Advanced or recurrent solid tumors* (phase II has been completed; NCT00729664; USA)Atezolizumab (Tecentriq™, MPDL3280A, RG7446)Human IgG1Roche & Genentech*Metastatic bladder cancer* (phase III, US FDA granted breakthrough therapy designation on May 31, 2014; priority review on March 14, 2016; accelerated approval on May 18, 2016); *metastatic NSCLC* (phase III, US FDA grants breakthrough therapy designation on February 1, 2015)Durvalumab (MEDI4736)Humanized IgG1AstraZeneca*Glioblastoma* (phase II is currently recruiting participants; NCT02336165; USA); *metastatic squamous cell carcinoma of the head and neck* (phase II is currently recruiting participants; NCT02207530; USA); *advanced or metastatic NSCLC* (phase III is currently recruiting participants; NCT02352948; Global study); *advanced colorectal cancer* (phase II is currently recruiting participants; NCT02227667; USA); *metastatic NSCLC* (first line phase III MYSTIC is current recruiting participants; NCT02453282; USA; first line phase III ARCTIC is current recruiting participants; NCT02352948; Global); *metastatic bladder cancer* (US FDA granted breakthrough therapy designation for PD-L1-positive tumors in patients who progressed during or after one standard platinum-based regimen on February 17, 2016)Avelumab (MSB0010718C)Fully humanized IgG1Merck KGaA, EMD Serono, Pfizer*Advanced solid tumors* (phase I with consecutive parallel group expansion; currently recruiting participants in multiple tumor types and settings; NCT01772004; USA); *metastatic NSCLC* (phase III is currently recruiting participants after failure of a platinum-based doublet; NCT02395172; and first line versus platinum doublet; NCT02576574; USA)PD-L2AMP-224PD-L2-IgG2a fusion proteinAmplimmune*Advanced cancer* (phase II has been completed; NCT01352884; USA)Last assessed information at ClinicalTrial.gov on December 28, 2015; updated FDA approvals on May 18, 2016. Italicized data highlights major cancer types in clinical evaluation*Abbreviations*: *CTLA-4* cytotoxic T-lymphocyte-associated protein 4, *NSCLC* non-small-cell lung cancer, *PD1* programed cell-death protein 1, *PDL1* programed cell-death ligand 1

Immune checkpoints normally maintain self-tolerance, regulate the amplitude and duration of T cell responses, and prevent tissue damage. PD-1 and PD-L1 immune checkpoint blockade can restore the function of exhausted CD8 T cells in chronic viral infection, augmenting the existing tumor-specific immunity \[[@CR20], [@CR21]\]. Nevertheless, immune checkpoint inhibitors can override immune self-tolerance, inducing a unique syndrome of autoimmune and autoinflammatory side effects (i.e., irAEs) \[[@CR22]\]. Many of these irAEs resemble autoimmune diseases, such as autoinflammatory rheumatic disease, dermatologic disease, colitis, hepatitis, and endocrinopathies \[[@CR23]\]. Therefore, almost all immunotherapy clinical trials have excluded individuals with preexisting autoimmune diseases, although a recent study demonstrates that the use of ipilimumab in cancer patients with autoimmune diseases is safe and effective \[[@CR24]\]. However, a recent study showed the safety and efficacy of using anti-CTLA-4 antibody in patients with autoimmune disease \[[@CR24]\]. Early detection and effective management of these irAEs are pivotal for a favorable clinical outcome. Theoretically, cytotoxic T cells against tumors and normal organs are different subclones that may not need to be activated in parallel. Further studies are warranted to specifically enhance tumor-specific cytotoxic T cell response and avoid unnecessary T cell response to normal tissues.

Biology and mechanisms of PD-1 and PD-L1 molecules {#Sec3}
==================================================

PD-1 (CD279) is expressed on many cell types including T cells, B cells, natural killer T cells, activated monocytes, and dendritic cells (DCs) in humans and mice \[[@CR25]\]. In normal human lymphoid tissues, PD-1 is detected on germinal center-associated T cells \[[@CR26]\]. PD-1 binds to the ligand PD-L1 (B7-H1, CD274) or PD-L2 (B7-DC, CD272). PD-L1 is typically expressed on the surface of tumor cells \[[@CR27]\]. PD-L1 is also constitutively expressed on other cell types such as T and B cells, DCs, macrophages, mesenchymal stem cells, and bone marrow-derived mast cells \[[@CR28]\]. Cell surface expression of PD-L1 can be upregulated on both tumor cells and other cell types after treatment with type I or type II interferons (IFNs) \[[@CR29], [@CR30]\], radiation \[[@CR31]--[@CR33]\], or chemotherapy \[[@CR34]--[@CR38]\]. Additionally, radiotherapy may induce direct tumor-cell killing and multiple immunomodulatory changes that can potentially influence the effectiveness of immunotherapy \[[@CR31]--[@CR33]\].

Engagement of PD-1 by its ligands, either PD-L1 or PD-L2, induces a negative control signal resulting in the inhibition of T cell proliferation, cytokine production, and cytotoxic activity. PD-L1 can provide inhibitory signals to activated T cells through interactions with the surface receptor PD-1 or CD80 \[[@CR25], [@CR39]\]. These signals enable PD-L1-expressing tumor cells to evade immune detection by NK cells or T cells \[[@CR40]--[@CR42]\]. PD-L2 is encoded by PDCD1LG2, which is essential for T cell proliferation and IFN production. PD-L2 can stimulate PD-1 receptor signaling, resulting in "T cell exhaustion," a temporary inhibition of activation and proliferation that can be reversed by the removal of PD-1 signal \[[@CR25]\].

Upregulation of PD-L1 on different tumor types inhibits the local antitumor T cell response. Figure [1](#Fig1){ref-type="fig"} illustrates the expression and complex interaction of key molecules and co-stimulatory ligand receptors between tumor and immune cells in tumor microenvironment (TME), and the two potential mechanisms proposed to understand the biology and function of PD-L1 on tumor cells \[[@CR43]\]. While constitutive oncogenic signals (such as protein kinase B (AKT), epidermal growth factor receptor (EGFR), KRAS pathways) upregulate PD-L1 expression on tumors as innate (tumor cell intrinsic) resistance (Fig. [1](#Fig1){ref-type="fig"}, left) \[[@CR44]--[@CR48]\], inflammatory signals generate cytokine-induced PD-L1 expression on either tumor cells or immune cells (myeloid suppressor cells, dendritic cell, macrophage, and lymphocytes) in the tumor microenvironment as adaptive resistance (Fig. [1](#Fig1){ref-type="fig"}, right) \[[@CR49], [@CR50]\]. Preclinical studies have demonstrated that blocking the PD-L1/PD-1 interaction increases the numbers of effector T cells, augments cytolytic activity of tumor-specific T cells, enhances the production of pro-inflammatory cytokines, brings effector T cells to the tumor sites, reduces numbers and suppression of Tregs at the tumor site, and downregulates the production of suppressive cytokines IL-10 \[[@CR51]--[@CR54]\]. Tumor-infiltrating T cells may also be functionally inert, due in part to the expression of PD-1 along with other inhibitory receptors \[[@CR27], [@CR55]\]. The hallmarks of the PD-1/PD-L1 blockage effect include immune modulation at tumor site, direct targeting of tumor-induced immune defects, and repairing ongoing tumor immunity. PD-1 deletion in mice can lead to autoimmunity, most notably when bred onto backgrounds of autoimmune-susceptible mouse strains \[[@CR56], [@CR57]\]. In multiple syngeneic mouse tumor models, blockade of PD-1 or its ligands promotes antitumor activity \[[@CR58], [@CR59]\]; anti-PD-1 activity in vivo can be enhanced by combination with antibodies to other T cell-negative regulators, such as CTLA-4 and LAG-3 \[[@CR60]--[@CR62]\]. A recent study suggests that PD-L1 is an independent prognostic marker in melanoma, defining a tumor subset with distinct genetic and morphophenotypic features \[[@CR63]\].Fig. 1Schema interaction between tumor and immune cells. Full activation of T-lymphocytes requires the coordinated participation of several surface receptors on effector T cells and antigen-presenting cells (APCs) or tumor cells. The main route of T cell stimulation is driven by antigens recognized in the form of short polypeptides associated with MHC antigen-presenting molecules. However, the functional outcome of T cell stimulation towards clonal expansion and effector function acquisition is contingent on the contact of additional surface receptor-ligand pairs and on the actions of cytokines in the tumor microenvironment. While some of those interactions are inhibitory (in *red*), others are activating and are collectively termed co-stimulatory (in *green*) receptors. Communication between T cells and APCs is bidirectional. In some cases, this occurs when ligands themselves signal to the APC. In other cases, activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on APCs. Tumor cells can upregulate PD-L1 expression via either the constitutionally activated oncogenic signaling (*left*, innate/intrinsic immune resistance) or the immune modulator-induced signaling pathways (*right*, adaptive immune resistance). *Abbreviations*: *APC* antigen-presenting cells, *DC* dendritic cell, *IL-2R* IL-2 receptor, *MDSCs* myeloid-derived suppressor cells, *Teff* effector T cell, *Treg* regulatory T cells, *IDO* indoleamin 2,3-dioxygenase, *TIM-3* T cell immunoglobulin domain and mucin domain, *LAG* lymphocyte-activation gene, *BTLA* B- and T-lymphocyte attenuator, *HVEM* herpes virus entry mediator, *TIGIT* T cell immunoreceptor with Ig and ITIM domains, *GITR* glucocorticoid-induced tumor necrosis factor receptor, *ICOS* inducible costimulators, *CEACAM* carcinoembryonic antigen-related cell adhesion molecule, *TSMA* tumor-specific mutant antigens, *JNK*, c-Jun N-terminal kinase, *MEK/ERK*, mitogen/extracellular signal regulated kinase, *PI3K*, phosphatidylinositol 3-kinase, *STAT*, signal transducer and activator of transcription, *NFκB*, nuclear factor kappa-light-chain-enhancer of activated B cells

Clinical efficacy of PD-1/PD-L1 blockade therapies and PD-L1 expression {#Sec4}
=======================================================================

Nivolumab and pembrolizumab are the first generation PD-1 immune checkpoint blockade antibodies. Nivolumab inhibits the interaction between PD-1 and its ligands, PD-L1, and PD-L2 with similar IC~50~ values (2.52 and 2.59 nmol/L, respectively). Nivolumab enhances T cell reactivity in the presence of a T cell receptor stimulus at the low concentration (\~1.5 ng/mL) without nonspecific lymphocyte activation. Nivolumab also enhances the production of inflammatory cytokines in assays such as the human T cell/DC-mixed lymphocyte reaction (MLR) assays, and Staphylococcal enterotoxin B (SEB), and cytomegalovirus (CMV) recall response assays. In addition, nivolumab increases antigen-specific CD8^+^ T cell responses in patients with melanoma \[[@CR64]\]. Nivolumab completely restored CD4^+^ T-responder cell proliferation and partially restored IFNγ production. Nivolumab also overcomes Treg suppression of CD8^+^ T cells by increasing resistance to Treg suppression and also by directly limiting suppressive capacity of Treg \[[@CR65]\]. This was demonstrated in monkeys when increased numbers of CD8^+^ T-effector memory cells were detected in CMV-positive peripheral blood after repeated treatment at the highest dose of nivolumab for 3 months. Similarly, marked accumulation of CD8^+^ effector memory T cells in lymphoid organs and tissues of PD-1-deficient mice has been described \[[@CR66]\].

Both nivolumab and pembrolizumab have shown significant survival benefit in some patients with advanced melanoma, NSCLC, and renal cell carcinomas in early clinical trials (Table [1](#Tab1){ref-type="table"}). These agents were generally well tolerated, even in elderly patients with prolonged dosing. Lower tumor response rates have been observed in never smokers and patients with EGFR mutations or ALK rearrangements when compared to heavy smokers. Table [2](#Tab2){ref-type="table"} summarizes this clinical efficacy data from four of the most studied PD-1 and PD-L1 inhibitors at various stages of clinical development. As only subsets of patients are benefiting from the PD-1/PD-L1 immune checkpoint blockade therapies, it is important to try to select for this population so that patients less likely to improve with therapy can be spared toxicities. An additional challenge is that response criteria used for standard therapy may not be applicable for immunotherapy. Unlike standard therapeutics in which tumor response is measured by a variety of radiographic and laboratory tests every 6--8 weeks, delayed tumor responses due to the time required for activation and function of effector T cells are frequently observed in cancer patients treated with immune checkpoint blockade therapies. In some patients, tumor regression persisted after discontinuation of PD-1 blockade therapy \[[@CR67]\]. Evaluating responses appropriately and identifying patients who are most likely to respond are important aspects of immunotherapy that continue to be developed.Table 2Summary of reported clinical efficacy of PD-1/PD-L1 inhibitorsAgentClinical trials identifierPhase of clinical trialSample size (no. Pt)Patient populationBiomarkerRegimenTumor responses (ORR)Median PFS (months)OS (months; median unless otherwise specified)Reference: author (year)NivolumabNCT01642004 (CheckMate 017)Phase III272 all: 135 nivolumab, 137 docetaxelAdvanced squamous NSCLC with disease progression during or after first-line chemotherapyPD-L1-positive tumor cellsNivolumab 3 mg/kg IV every 2 weeks20 %3.59.2Brahmer J (2015) \[[@CR125]\]Docetaxel 75 mg/m^2^ IV every 3 weeks9 %2.86NCT01673867 (CheckMate 057)Phase III582 all: 292 nivolumab, 290 DocetaxelAdvanced non-squamous NSCLC after platinum-based doublet chemotherapyPD-L1-positive tumor cellsNivolumab 3 mg/kg IV every 2 weeks19 %2.312.2Borghaei H (2015) \[[@CR126]\]Docetaxel 75 mg/m2 IV every 3 weeks12 %4.29.4NCT01668784 (CheckMate 025)Phase III821 all: 406 nivolumab, 397 EverolimusAdvanced clear-cell renal-cell carcinoma with one or two regimens of anti-angiogenic therapyPD-L1-positive tumor cellsNivolumab 3 mg/kg IV every 2 weeks25 %4.625Motzer RJ (2015) \[[@CR127]\]Everolimus 10 mg orally daily5 %4.419.6NCT01721746 (CheckMate 037)Phase III631 all: 272 nivolumab,133 investigators choice of chemoUnresectable or metastatic melanoma after ipilimumab or ipilimumab and BRAF inhibitor if BRAF positivePD-L1-positive tumor cellsNivolumab 3 mg/kg IV every 2 weeks32 %4.7NAWeber JS (2015) \[[@CR128]\]Chemo: either dacarbazine 1000 mg/m2 IV every 3 weeks or carboplatin AUC = 6 plus paclitaxel 185 mg/m2 IV every 3 weeks11 %4.2NANCT01927419 (CheckMate 069)Phase III142 all: 95 nivolumab + ipilimumab, 47 ipilimumabUnresectable or metastatic melanoma treatment naïve with measurable diseaseTissue available for PD-L1 biomarker analysisNivolumab 1 mg/kg IV every 3 weeks × 4 doses plus ipilimumab 3 mg/kg IV every 3 weeks × 4 doses, then maintenance nivolumab 3 mg/kg IV every 2 weeksBRAF wild type: 61 %; BRAF mutation: 52 %BRAF wild type: NR; BRAF mutation: 8.5NAPostow MA (2015) \[[@CR4]\]Same dose schedule with nivolumab placebo in both the combination and maintenance phaseBRAF wild type: 11 %; BRAF mutation: 22 %BRAF wild type: 4.4; BRAF mutation: 2.7NANCT01721772 (CheckMate 066)Phase III418 all: 210 nivolumab, 208 dacarbazineUntreated metastatic melanoma without BRAF mutationTissue available for PD-L1 biomarker analysisNivolumab 3 mg/kg IV every 2 weeks plus placebo every 3 weeks40 %5.11-year OS: 72.9 %Robert C (2015) \[[@CR129]\]Dacarbazine 1000 mg/m2 IV every 3 weeks plus placebo every 2 weeks13.9 %2.21-year OS: 42.1 %NCT01844505 (CheckMate 067)Phase III945 all: 316 nivolumab, 314 combination, 315 ipilimumabUntreated, unresectable stage III or IV melanomaTissue available for PD-L1 biomarker analysisNivolumab 3 mg/kg IV every 2 weeks (plus ipilimumab placebo)43.7 %6.9NALarkin J (2015) \[[@CR130]\]Nivolumab 1 mg/kg IV every 3 weeks plus ipilimumab 3 mg/kg IV every 3 weeks × 4 doses; then maintenance nivolumab 3 mg/kg IV every 2 weeks58 %11.5Ipilimumab 3 mg/kg IV every 3 weeks (plus nivolumab placebo)19 %2.9NCT01721759 (CheckMate 063)Phase II single arm trial117Advanced NSCLCPD-L1-positive tumor cellsNivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxic effects14.5 %1.98.2Rizvi NA (2015) \[[@CR131]\]NCT00730639Phase I with expansion cohorts107Advanced melanomaUnselectedNivolumab at 1, 3, or 10 mg/kg every 2 weeks for up to 96 weeks31 %3.716.8Topalian SL (2014) \[[@CR67]\]Phase I with expansion cohorts34Previously treated advanced RCCUnselectedNivolumab at 1, 3, or 10 mg/kg every 2 weeks for up to 96 weeks29 %7.322.4McDermott DF (2015) \[[@CR132]\]Phase II with expansion cohorts129Heavily pretreated advanced NSCLCUnselectedNivolumab at 1, 3, or 10 mg/kg every 2 weeks for up to 96 weeks17 %2.69.9Gettinger SN (2015) \[[@CR133]\]PembrolizumabNCT01866319 (KEYNOTE-006)Phase III834 all: 279 pembrolizumab, 277 pembrolizumab, 278 ipilimumabUnresectable stage III or IV melanomaPD-L1-positive tumor cellsPembrolizumab 3 mg/kg IV every 2 weeks33.7 %5.5NARobert C (2015) \[[@CR134]\]Pembrolizumab 3 mg/kg IV every 3 weeks32.9 %4.1Ipilimumab 3 mg/kg IV every 3 weeks11.9 %2.8NCT01704287 (KEYNOTE-002)Phase II540 all: 180 pembrolizumab, 181 pembrolizumab, 179 chemotherapyIpilimumab-refractory melanomaWill be reported with the final overall survival analysisArm A 2 mg/kg (*n* = 180)21 %5.4NARibas A (2015) \[[@CR135]\]Arm B 10 mg/kg (*n* = 181)25 %5.8Chemotherapy4 %3.6NCT012958297 (KEYNOTE-001)Phase I495Advanced NSCLCPD-L1-positive tumor cellsPembrolizumab 2 or 10 mg/kg IV every 3 weeks or 10 mg/kg every 2 weeks over a 30-min period19.4 %3.712Garon EB (2015) \[[@CR5]\]Phase I655MelanomaUnselectedPembrolizumab 2 mg/kg every 3 weeks (Q3W), 10 mg/kg Q3W, or 10 mg/kg Q2W until unacceptable toxicity, disease progression, or investigator decision33 %12-month PFS 35 %23Adil Daud (2015) \[[@CR136]\]; Ribas A (2016) \[[@CR137]\]Phase I with expansion cohort173Advanced melanoma after at least 2 ipilimumab dosesUnselectedPembrolizumab 2 mg/kg IV every 3 week or 10 mg/kg IV every 3 weeks26 %2NARobert C (2014) \[[@CR138]\]NCT01848834 (KEYNOTE-012)Phase IB32Metastatic triple-negative breast cancerPDL-1-positive tumor cellsPembrolizumab 10 mg/kg IV every 2 weeks19 %6-month PFS 23.3 %NANanda R (2014) \[[@CR139]\]NCT1905657 (KEYNOTE-010)Phase II/III1034 all: 339 pembrolizumab, 343 pembrolizumab, 309 docetaxelPreviously treated PD-L1-positive advanced NSCLCPDL-1-positive tumor cellsPembrolizumab 2 mg/kg, IV every 3 weeks18 %3.9 months14.9Herbst RS \[2015\] \[[@CR140]\]Pembrolizumab 10 mg/kg, IV every 3 weeks18.5 %4.0 month17.3Docetaxel, 75 mg/m2 every 3 weeks9.3 %4.0 month8.2NCT01953692 (KEYNOTE-013)Phase IB15Hodgkin lymphomaUnselectedPembrolizumab 10 mg/kg IV every 2 weeks up to 2 years53 %NANAMoskowitz C (2014) \[[@CR141]\]Atezolizumab (MPDL3280A)NCT01846416Phase II205NSCLCPD-L1-positive tumor cellsAtezolizumab 1200 mg IV every 3 weeksThe highest ORR was seen in pts with PD-L1 TC3 or IC3 tumorsNANASpigel DR (2015) \[[@CR142]\]NCT01903993 (POPLAR)Phase II287Previously treated NSCLC patients (pts) were stratified by PD-L1 IC statusPD-L1-positive tumor cellsAtezolizumab 1200 mg IV every 3 weeks57 %2.712.6Spira AI (2015) \[[@CR143]\]; Fehrenbacher L (2016)Docetaxel 75 mg/m2 IV every 3 weeks24 %3.09.7NCT01375842Phase I35Metastatic melanomaPD-L1-positive tumor cellsAtezolizumab IV every 3 weeks for up to 1 year26 %24-week PFS 35 %NAOmid Hamid (2013) \[[@CR144]\]Phase I277Multiple cancer typesPD-L1-positive tumor cellsAtezolizumab intravenously every 3 weeks doses \>1 ml/kg18 %2.6NAHerbst RS (2014) \[[@CR145]\]NCT01633970Phase Ib37Untreated NSCLCPD-L1-positive tumor cellsAtezolizumab 15 mg/kg IV every 3 weeks with standard chemo dosing for 4--6 cycles followed by MPDL3280A maintenance therapy until progression67 %NANAStephen V (2015) \[[@CR146]\]Phase Ib14Arm A: refractory metastatic colorectal cancer; arm B: oxaliplatin-naive mCRCNot mentionedArm A: MPDL3280A 20 mg/kg every 3 weeks and bevacizumab (bev) 15 mg/kg every 3 weeks8 % (1/13) in arm ANANABendell, J.C. (2015) \[[@CR147]\]Arm B: MPDL3280A 14 mg/kg every 2 weeks, bev 10 mg/kg every 2 weeks and mFOLFOX6 at standard doses36 % (9/25) in Arm BNANAPhase Ib12Metastatic renal cell carcinomaNot selectedAtezolizumab 15 mg/kg given alone on cycle 1 day 1 and concurrently with 20 mg/kg every 2 weeks thereafter40 %NANASznol M (2015) \[[@CR148]\]Durvalumab (MEDI4736)NCT01693562Phase I/II198NSCLCTissue available for PD-L1 biomarker analysisDurvalumab 10 mg/kg IV every 2 weeks until unacceptable toxicity, disease progression, or for up to 12 months14 % (23 % in PD-L1+ tumors)NANARizvi NA (2015) \[[@CR149]\]Phase I13NSCLCTissue available for PD-L1 biomarker analysisDurvalumab 7 doses (1--25) across 6 cohorts (0.1--10 mg/kg every 2 weeks; 15 mg/kg every 3 weeks)NANANABrahmer JR (2014) \[[@CR150]\]Multi-arm expansion study62A squamous cell carcinoma of the head and neck expansion cohortTissue available for PD-L1 biomarker analysisDurvalumab IV every 2 weeks at 10 mg/kg for 12 months12 % (25 % in PD-L1+ pts)NANASegal NH (2015) \[[@CR151]\]Phase I26Advanced solid tumorsDurvalumab IV every 2 (q2w) or 3 weeks (q3w) in a 3 + 3 dose escalation with a 28-day (q2w) or 42-day (q3w) DLT windowNANANALutzky J (2014) \[[@CR152]\]NCT02088112Phase I10NSCLCUnselectDurvalumab cohort A received 3 mg/kg (starting dose) every 2 weeks plus gefitinib 250 mg QDNANANACreelan BC (2015) \[[@CR153]\]NCT02000947Phase Ib118 (102 eligible)NSCLCTissue available for PD-L1 biomarker analysisDurvalumab 10--20 mg/kg every 2 or 4 weeks plus tremelimumab 1 mg/kg (*N* = 56)23 % (6/26): 22 % (2/9) in PD-L1+ versus 29 % (4/14) in PD-L1-NANAAntonia SJ (2015) \[[@CR154]\]; Updated in Antonia SJ (2016) \[[@CR155]\]Durvalumab 10--20 mg/kg every 2 weeks plus tremelimumab 3 mg/kg (*N* = 34)20 % (5/25)Durvalumab 15 mg/kg every 4 weeks plus tremelimumab 10 mg/kg (*N* = 9)0 % (0/9)*Abbreviations*: *DLT* dose-limiting toxicity, *q2w* every 2 weeks, *q3w* every 3 weeks, *q4w* every 4 weeks, *QD* once daily, *BRAF* B-raf and v-raf murine sarcoma viral oncogene homologue B1, *NA* not available

Biomarkers for PD-1/PD-L1 blockade therapies {#Sec5}
============================================

Translational biomarker research is critical for the future of drug development for clinical immune checkpoint blockade therapy. Only one PD-L1 IHC has been approved as a companion diagnostic by the US FDA for patients with advanced NSCLC for pembrolizumab \[[@CR68]\]. The challenges in developing immuno-oncology biomarkers for clinical use have been recognized by regulatory agencies and professional societies such as the Society for Immunotherapy of Cancer (SITC) \[[@CR69]\]. Over the past several years, the SITC Immune Biomarkers Task force has provided the roadmap and regular updates on immune biomarker development \[[@CR70]--[@CR72]\]. Immunological changes in peripheral blood and tumor could potentially reflect tumor response in patients and serve as immune biomarkers. The immune monitoring assays had been developed to evaluate these potential biomarkers before and after immune checkpoint blockade therapies and investigate their correlation with clinical outcome (Fig. [2](#Fig2){ref-type="fig"}). These biomarkers could be classified into two groups: tumor-derived immune biomarkers and immune cell-derived biomarkers as discussed in the following sections. Table [3](#Tab3){ref-type="table"} summarizes currently available quantitative biomarker assays for immune checkpoint inhibitors.Fig. 2Immune monitoring strategies for patients receiving checkpoint blockage therapy. Technologies that are currently used to assess the potential immune biomarkers. **a** Tumor and immune cells in tumor specimens could be evaluated by immunohistochemical stain (IHC) or immunofluorescence assays, molecular or genetic profiling analysis, and cellular functional assays. The tumor microenvironment can be dissected histopathologically to characterize spatial relationships between tumor and immune infiltrates. Transcriptional profiling assays can evaluate changes in gene expression in both the tumor cells and lymphocytes. Deep sequencing techniques enable quantification of changes in individual T/B cell clonotypes. **b** Peripheral blood provides a minimally invasive way to allow serial monitoring of dynamic changes of immune biomarkers during cancer immunotherapy. The analysis of changes in cell counts with therapy, changes in cytokine levels, circulating tumor cells, tumor-derived nucleotides, and immune cells. **c** Flow cytometric analysis of TILs anPBMCs for quantitating the effect of therapy on immune subsets such as activated CD8 + PD1+ T cells, CD4 + FOXP3 + CD25^hi^ Tregs, or myeloid-derived suppressor cells. Using polychromatic flow cytometry, multiple surface and intracellular markers can be detected, allowing in-depth characterization of T cell phenotype and activation state. **d** Multifunctional flow T cell assay, MHC tetramer staining and ELISPOT can be used to analyze the presence and function of tumor-specific T cell subpopulations. *Abbreviations*: *PD-L1* programed death-1, *IHC* immunohistochemistry, *ELISPOT* enzyme-linked immunospot assay, *CTCs* circulating tumor cells, *WES* whole exome sequencing, *NGS* next-generation sequencing, *TIM-3* T cell immunoglobulin domain and mucin domain, *LAG* lymphocyte-activation gene, *ICOS* inducible costimulators, *MDSC* myeloid-derived suppressor cells, *HLA* human leukocyte antigenTable 3Currently available translational biomarker assays for immune checkpoint inhibitorsBiospecimenMethodTissue/cell typesProsConsReferences and recommended readingFFPEIHCTumor cells or tumor infiltrating immune cellsDirect detection; accurately pinpoint cancer cells; highly sensitive; simplicity; low costRequirement of trained pathologists; inconsistency for criteria used to score tumors such as PD-L1-positive or negativeHerbst R (2014) \[[@CR145]\]; Loughlin PA (2007) \[[@CR164]\]Multicolor IHCTumor cells or tumor infiltrating immune cellsBroad dynamic range; capability for multiplexing using different fluorescence channels; \>10 protein targets are identified in the same sample; amenability for co-localization studiesAbsence of rigorous quantitative tests; limitation in some biomarker-driven clinical trials; user must select combinations of dyesCarvajal-Hausdorf DE (2014) \[[@CR165]\]T cell receptor deep sequencingTILsT cell count information;\
T cell clonality in tumorHeterogeneous expression of TILRobbins HS (2013) \[[@CR100]\]Whole exome sequencing (WES)Tumor cellsCharacterization of tumor mutation load including nucleotide substitutions; structural rearrangements and copy number alterations; identification of the neoantigens and neoepitopes; affordable costRequire high-performance deep sequencing, computational bioinformatics support;\
The pipelines are still at early developmental phaseSnyder A (2014) \[[@CR104]\]; Rizvi NA (2015) \[[@CR105]\];\
Bouffet E (2016) \[[@CR107]\];\
Chen K-H (2016) \[[@CR166]\]\
Hugo W (2016) \[[@CR106]\]BloodELISPOT assays (IFNγ and granzyme B)T cells in PBMCsDetection of tumor antigen-specific CD4^+^ and CD8^+^ T cell response with good assay sensitivity;\
Relatively well validated assayA poor correlation with clinically relevant immune responsesShafer-Weaver K (2006) \[[@CR167]\]; Janetzki S (2008) \[[@CR95]\] Malyguine A (2012) \[[@CR94]\]; Janetzki S (2015) \[[@CR93]\];Flow cytometry (tetramer, polyfunctional analysis)T cells in PBMCsAssessment of tumor antigen-specific CD4^+^ and CD8^+^ T cells response; measure multiple functions; detection of neoantigen-specific CD8 + PD-1+ T cells; minimally invasiveMerely in lab research, not as routine clinical monitoring yetYuan J (2008) \[[@CR84]\]; Attic S (2011) \[[@CR85]\]; McNeil LK (2013) \[[@CR86]\]; Barrera L (2015) \[[@CR168]\]; Gros A (2016) \[[@CR118]\]Flow cytometry phenotype stainingWhole blood immune phenotypeAnalyses of the frequency and proliferation of different subsets of immune cells; routine operationDedicated resource and staff to perform the analysesStreitz M (2013) \[[@CR169]\]; van Dongen JJ (2012) \[[@CR170]\]RNA-Seq (NGS)T cells in PBMCsIdentification of genetic variants; a broader dynamic range; detection of more differentially expressed genes; fast and high efficiencyMore expensive than microarray; more complex for analysis; bulk signature, not single cell signals; need more validationZhao S (2010) \[[@CR171]\]qPCR assayT cells in PBMCsHigh specificity; able to detect the reactivity of low-frequency T cells in the peripheral blood of metastatic cancer patientsBulk signature, not single cell signals; need more validationKammula US (2008) \[[@CR172]\]Flow cytometryCTCsQualitative analysis at the single cell level in a relatively short period of time; decrease the amount of blood needed; provide valuable information regarding the frequency, phenotype and/or the functionality of T cellsExpensive; need more validationZaritskaya L (2010) \[[@CR83]\]Cell sieve microfiltration assay and QUASR techniqueCTCsPD-L1 levels from CTCs or CAMLs serves as a surrogate for PD-L1 expression in tumor; as a marker for immunotherapy responseLimited in lab research; need more validationSteven HL (2015) \[[@CR173]\]; Adams DL (2014) \[[@CR174]\]*Abbreviations*: *FFPE* formalin-fixed paraffin-embedded, *PD-L1* program death-1, *TIL* tumor-infiltrating lymphocytes, *IHC* immunohistochemistry, *CAMLs* cancer-associated macrophage-like cells, *ELISPOT* enzyme-linked immunospot assay, *CTL* cytotoxic T-lymphocytes, *CTCs* circulating tumor cells, *PBMC* peripheral blood mononuclear cell, *WES* whole exome sequencing, *NGS* next-generation sequencing

Current immune monitoring assays {#Sec6}
--------------------------------

### IHC staining {#Sec7}

PD-L1 is the best studied immuno-oncology biomarker to date. Currently, PD-L1 IHC using 22C3 antibody is the only FDA-approved companion diagnostic for selecting NSCLC patients for pembrolizumab \[[@CR68]\]. Table [4](#Tab4){ref-type="table"} summarizes the IHC assays used for PD-L1 expression using baseline archival tumor specimens in these clinical studies \[[@CR73]\]. There are many variables in these IHC assays. First, the time between sample collection and treatment with a PD-1 or PD-L1 inhibitor is not controlled. Second, tumor cells, immune cells, as well as stroma cells can express PD-L1 with considerably heterogeneity within the tumor microenvironment. Third, PD-L1 expression is induced by IFNγ during disease progression and treatment. Fourth, different PD-L1 antibodies were used for different immune checkpoint blockade clinical studies. Currently, there is no validated antibody for IHC staining for this class of immune checkpoint inhibitors---each sponsor uses different antibodies. Antibodies staining tumor cells or stroma cells may have different PD-L1 epitopes (Table [4](#Tab4){ref-type="table"}). An additional challenge is that none of the commercial PD-L1 IHC test has been validated in terms of clinical outcomes. Head-to-head comparisons among three different commercially available PD-L1 assays (Dako 22C3, Dako 28-8, and Ventana SP263 as the reference) using 500 formalin-fixed, paraffin-embedded archival samples of NSCLC tissue obtained from commercial sources found 91 to 95 % correlation, which is comparable to typical within assay agreement for IHC across the dynamic range at multiple cutoffs \[[@CR74]\]. A recent meta-analysis demonstrates that PD-L1 expression is significantly associated with clinical response to anti-PD-1/PD-L1 antibodies in patients with malignant melanoma (MM) or non-squamous NSCLC. However, a proportion of PD-L1-negative patients also benefits from anti-PD-1 therapy in MM and squamous-NSCLC. Thus, expression of PD-L1 in tumor tissues cannot be used as a predictive biomarker of eligibility for treatment with anti-PD-1/PD-L1 antibodies. It may represent a correlation marker for non-squamous NSCLC and melanoma \[[@CR75]\].Table 4Immunohistochemistry assays for PD-L1 expressionDrugAntibody (marker)Rx lineTumor typeTargeted cellsTumor specimenCutoff point (%)ORR % in IHC+ cases (95 % CI)ORR % in IHC− cases (95 % CI)Predictive role*P* valueReferencesNivolumab28-8 rabbit (Dako)1 LMelanomaTCsArchival FFPE or new biopsy558 (46,69)41 (35,48)Yes0.001Larkin J (2015) \[[@CR130]\]Nivolumab + ipilimumab72 (60,82)55 (48,62)Yes0.001Nivolumab≥2 L544 (30,58)20 (11,32)YesNAWeber JS (2015) \[[@CR128]\]Nivolumab + ipilimumab1 L558 (37,78)55 (42,69)No\>0.05Postow MA (2015) \[[@CR4]\]Nivolumab1 L553 (41,64)33 (25,42)No\>0.05Robert C (2015) \[[@CR129]\]≥2 LNSCLCTCsArchival FFPE or new biopsy131 (23,40)9 (5,16)Yes0.002Paz-Ares L (2015) \[[@CR156]\]; Updated in Borghaei H (2015) \[[@CR126]\]536 (26,46)10 (6,17)Yes0.0021037 (27,48)11 (6,17)Yes0.002≥2 LArchival FFPE117 (9,29)17 (8,29)No0.9364Brahmer JR (2015) \[[@CR125]\]521 (10,37)15 (8,25)No0.29081019 (8,36)16 (9,26)No0.6411≥2 LArchival FFPE120 (5,35)13 (2,28)No\>0.05Rizvi NA (2015) \[[@CR131]\]524 (5,43)14 (3,25)No1 LArchival FFPE531 (NA)10 (NA)No\>0.05Gettinger SN (2015) \[[@CR157]\]Nivolumab + ipilimumab1 LArchival FFPE519 (NA)14 (NA)No\>0.05Antonia SJ (2014) \[[@CR158]\]Nivolumab5H1 and anti-PD-1 monoclonal M3≥2 LArchival FFPE539 (34,44)6 (1,12)Yes0.025Taube JM (2014) \[[@CR113]\]Pembrolizumab22C3 mouse (Dako)≥1 LNSCLCTCs and ICsNew biopsy5045 (33,57)17 (10,25)Yes0.001Garon EB (2015) \[[@CR5]\]1 LNew biopsy5047 (23,72)19 (8,38)YesNARival NA (2015) \[[@CR159]\]AnyArchival FFPE125 (NA)13 (NA)YesNAGaron EB (2014) \[[@CR160]\]≥1 LArchival FFPE5030 (23,39)9.8 (NA)YesNAHerbst RS (2015) \[[@CR140]\]29 (22,37)10.7 (NA)1 LArchival FFPE5016 (NA)10 (NA)YesNAGaron EB (2014) \[[@CR161]\]Atezolizumab (MPDL3280A)SP142 rabbit (Roche Ventana)≥2 LNSCLCTCs and ICsArchival FFPE and new biopsy5045 (23,68)14 (6,25)YesNALeora H (2015) \[[@CR162]\]≥2 LNSCLC1+31 (25,37)20 (14,26)Yes0.015Herbst RS (2014) \[[@CR145]\]Solid Tumor1+29 (27,31)13 (10,16)Yes0.007≥2 LNSCLC2+18 (NA)8 (NA)YesNASpira AI (2015) \[[@CR143]\]Durvalumab (MEDI-4736)SP263 rabbit (Roche Ventana)≥2 LNSCLCTCsArchival FFPE and new biopsy2539 (NA)5 (NA)YesNASegal NH (2014) \[[@CR163]\]33 (13,59)30 (16,47)No for comboNAAntonia SJ (2016) \[[@CR155]\];22 (3, 60)29 (8, 58)No for monotherapyNA*NA* not available

The presence of tumor-infiltrating lymphocytes (TILs) at tumor microenvironment has been associated with an improved clinical outcome \[[@CR76]--[@CR78]\], regardless of cancer treatment. TIL counts are primarily measured by IHC \[[@CR79]\]. Recent development of multicolored immunohistochemistry staining resulted in a multiplex of up to seven fluorescent dyes effectively interrogated in microscopes equipped with a multispectral camera \[[@CR80]\]. The multispectral fluorescent IHC with a panel including CD3, CD8, FoxP3, CD163, and PD-L1 was used to quantify the density of TIL subpopulation in advanced melanoma patients.

### Flow cytometry staining {#Sec8}

Flow cytometry traditionally uses fluorochrome-labeled antibodies to identify cellular protein expression of the target cells. Flow cytometric analysis of peripheral blood mononuclear cells (PBMCs) and TILs can quantitate the effect of therapy on low-frequency immune subsets such as Treg, MDSC, and activated CD8^+^ T cells \[[@CR81]\]. The biggest advantage of flow cytometry is the combination of multiparameter measurements in a high-throughput manner. With recent advances in laser and fluorochrome technology, commercially available systems allow for detection of up to 18 colors at analysis rates of more than 20,000 events per second. This tremendous power allows for the analysis of multiple characteristics of rare cells such as tumor antigen-specific T-lymphocytes, including their phenotype and functional activity \[[@CR82]\]. Flow cytometric assays are currently widely used for the enumeration and phenotypic characterization of lymphocytes, measuring cytokines, secreted molecules, intracellular signaling, function, and cell proliferation \[[@CR83]\]. Using polychromatic flow cytometry, multiple surface and intracellular markers can be detected, allowing in-depth characterization of T cell phenotype and activation state \[[@CR84]\]. In addition to flow cytometry, antigen-loaded soluble major histocompatibility complex (MHC) tetramer stains can be used to analyze tumor-specific T cell subpopulations \[[@CR82]\]. This tetramer/pentamer staining has been used for phenotypic and quantitative analysis of antigen-specific CD8 T cells \[[@CR85], [@CR86]\]. The human leukocyte antigen (HLA) system is a gene complex encoding the MHC proteins in humans. HLA-peptide complexes binding to T cell receptors could further define the specificity for epitopes and alleles \[[@CR87]\]. Recently, mass cytometry or CyTOF which replace the fluorescent labels with heavy metal ions is under investigation for its application in immune biomarker research \[[@CR88]\].

### ELISA and protein microarray {#Sec9}

Biomarkers in the blood have been pursued because specimens are easy to collect and assays are available for serial monitoring and quantitative measurements \[[@CR89]\]. Enzyme-linked immunoabsorbent assay (ELISA) is widely used to assess the production of soluble mediators such as cytokines, chemokines, and tumor antigen-specific antibodies in peripheral blood before and after treatment. Novel protein microarray technologies such as ProtoArray® are available to analyze the serological response of up to 9000 proteins simultaneously \[[@CR90]--[@CR92]\].

### ELISPOT {#Sec10}

Enzyme-linked immunospot (ELISPOT) assays are robust and standardized tests that quantify both the frequency and function of T or B cells at the single cell level. Both PBMCs and isolated CD4^+^ and CD8^+^ T cell subsets could be stimulated by antigens and cultured in a 96-well plate with a nitrocellulose membrane coated with antibodies for cytokines of interest. These assays, such as the IFNγ ELISPOT, have gained increasing popularity for monitoring clinical trials and in basic research \[[@CR93]--[@CR95]\]. Results from various clinical trials, including peptide and whole tumor cell vaccination and cytokine treatment, showed the suitability of the IFNγ ELISPOT assay for monitoring T cell response \[[@CR96]\]. ELISPOT assays revealed that 75 % of melanoma patients vaccinated with antigenic peptide demonstrated specific immune responses \[[@CR97], [@CR98]\]. Besides IFNγ, other cytokines such as IL-2, IL-5, IL-10, IL-17, granzyme B, TNF, and granulocyte-macrophage colony-stimulating factor (GM-CSF) are commonly measured by ELISPOT assays. It has been expanded to more than 2\~3 parameters with the introduction of fluorescent dyes \[[@CR99]\].

### T cell or B cell receptor deep sequencing {#Sec11}

To develop a robust, quantitative method with high reproducibility, Robins et al*.* \[[@CR100]\] uses a digital droplet PCR technique call a Quan*TIL*fy assay. High-throughput quantitative sequencing of the rearranged TCR β genes uses the ImmunoSeq assay. The TCR loci undergo somatic gene rearrangements in the 52 variable (V), diversity (D), and 13 joining (J) regions of the β chain and variable (V) and joining (J) regions of α chain. There are 52 Vβ segments and 13 Jβ segments that can rearrange. With the right TaqMan probes-DNA from T cells can be easily identified with reference to total DNA, as was shown when purified human T cells were obtained from a healthy donor and then diluted and mixed with human lung fibroblasts at different ratios. This technique can also identify clonal expansion (the mark of the adaptive immune response). TCR deep sequencing has been used to show the correlation between TCR repertoire and clinical response to cancer immunotherapy in patients with melanoma or prostate cancer treated with ipilimumab \[[@CR101]\]. Creation of a responder library for TCR repertoire will greatly advance the field, especially for genetically modified TCR cell transfer therapy.

### WES for mutation load {#Sec12}

The cancers that respond best to PD-1 inhibitors, such as advanced melanoma and NSCLC, are the tumor types that are genetically very complex with a high nonsynchronous mutation load. This discovery led to an interest in neoantigens (i.e., tumor-specific mutant antigens (TSMAs)) that are immunogenic \[[@CR102]\]. The advances in both affordable next-generation sequencing (NGS) technology and bioinformatics make it feasible to assess the full mutation load in individual tumors and to identify neoantigens by comparing WGS of tumor and normal tissues \[[@CR103]\]. Computation prediction algorithms and the tandem mini-gene library allow for the evaluation of the immunogenicity of both CD4^+^ and CD8^+^ T cell neoepitopes. Mutation load and neoepitopes have been explored for their correlation with clinical outcomes in cancer patients treated with the PD-1/PD-L1 immune checkpoint blockade \[[@CR104]--[@CR107]\]. However, whole exome sequencing (WES) currently is not used in routine clinical practice. The role of tumor load assessed in targeted exome sequencing (TES) assays in predicting response to immune checkpoint inhibitors remains to be determined.

### Genetic susceptibility {#Sec13}

Genetic factors are known to modulate the immune response to a therapeutic protein product. In particular, some HLA haplotypes may predispose patients to developing either exceptional or undesirable antibody responses to immune checkpoint blockage therapies \[[@CR108]\]. If both are appropriate and feasible, HLA mapping studies may help define a subset of patients who are at increased risk. Moreover, genetic polymorphisms in cytokine genes may upregulate or downregulate immune responses \[[@CR109]\], which is why the FDA recommends that researchers evaluate the genetic factors that may modulate the immune response to a therapeutic protein. For example, the subset of patients who generate neutralizing antibodies to IFNβ products are more likely to possess distinct HLA haplotypes \[[@CR108]\]. Thus, knowledge of the heightened susceptibility of patients with such HLA haplotypes may guide us to prevent such responses or pursuit other treatment options (<http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm338856.pdf>).

Tumor-derived immune biomarkers {#Sec14}
-------------------------------

### PD-L1 expression {#Sec15}

Upregulation of PD-L1 expression level has been reported in many different cancer types (e.g., melanoma (40--100 %), NSCLC (35--95 %), and multiple myeloma (93 %)). High levels of PD-L1 expression have been linked to poor clinical outcomes \[[@CR42], [@CR110], [@CR111]\]. Until now, anti-PD-L1 IHC on tumor specimens is the most commonly used biomarker for selecting patients who are likely to respond to treatments \[[@CR89]\]. Constitutively overexpressed PD-L1 in melanoma is associated with poor clinical outcome \[[@CR112]\]. However, the PD-L1 overexpression in the context of CD8-positive cells is associated with a better prognosis \[[@CR113]\]. Although PD-L1 IHC using the 22C3 antibody has been approved by the US FDA as the only predictive companion diagnostic for selecting NSCLC patients for pembrolizumab, tumor responses have been seen in low PD-L1-expressing tumors. Conflicting results have been reported with other PD-L1 antibodies and drugs. Table [4](#Tab4){ref-type="table"} summarizes the reported data of PD-L1 IHC in current clinical trials.

Several tumor characteristics, such as a high mutation load, smoking-related tumors, and tumors with mismatch repair genes are associated with improved objective tumor response rate (ORR), durable clinical benefit (DCB), and PFS to immune checkpoint blockade antibodies. Notably, whole exome sequencing has revealed that a nonsynonymous mutation load of \>200 per tumor correlates with clinical responses to PD-1 mAb in NSCLC, melanoma, and colorectal cancer with microsatellite instability (MSI; i.e., mutations in DNA mismatch repair genes) \[[@CR114]--[@CR116]\]. Rizvi and his colleagues showed that mutation load correlates with improved ORR (63 versus 0 %), DCB (73 versus 13 %), and PFS (14.5 versus 3.7 months) \[[@CR105]\]. Moreover, the efficacy was associated with a molecular smoking signature. The ORR was 56 and 17 % in transversion-high tumors and transversion-low tumors, respectively; the rate of DCB was 77 versus 22 %, respectively; and the PFS was also significantly longer in transversion-high tumors compared to transversion-low tumors. Efficacy was also connected with higher neoantigen burden, but additional genetic features are likely to play a role in determining the tumor response \[[@CR116], [@CR117]\]. Neoantigen-specific CD8+ T cell responses paralleled tumor regression in one responder, implying that anti-PD-1 therapy enhanced neoantigen-specific T cell reactivity \[[@CR118]\].

Immune cell-derived biomarkers {#Sec16}
------------------------------

TIL cells have been shown to express significantly higher levels of PD-1 than T cells in normal tissue \[[@CR119]\]. The tumor microenvironment may secrete pro-inflammatory cytokines to upregulate the expression of PD-1 on TIL cells to ensure that they can respond to the high levels of PD-L1 expressed on the tumor \[[@CR120]\]. Preexisting CD8^+^ T cells distinctly located at the invasive tumor margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis \[[@CR121]\]. The proliferation of intratumoral CD8^+^ T cells directly correlated with radiographic reduction in tumor size in metastatic melanoma patients treated with pembrolizumab. Pretreatment samples obtained from responding patients showed higher numbers of CD8^+^ T cells, PD-1, and PD-L1-expressing cells at the invasive tumor margin and inside tumors, with a more clonal TCR repertoire. Using multivariate analysis, researchers established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Their findings indicate that tumor regression after PD-1 blockade requires preexisting CD8^+^ T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance. In addition, the tumor microenvironment can be dissected histopathologically in order to characterize spatial relationships between tumor and immune infiltrate, and transcriptional profiling assays can evaluate changes in gene expression in both the tumor and in lymphocytes \[[@CR122]\].

Given that TIL in the tumor microenvironment affects the prognosis of the tumor, a new TNM Immune system (TNM-I) system has been proposed and is currently being validated by an international consortium \[[@CR123]\]. Early studies suggest that activated T cells are not pharmacodynamic markers of nivolumab treatment \[[@CR124]\]. It remains to be determined whether nivolumab treatment increases CD8 effector memory cells in cancer patients. With technical advances, detection of CD8-positive, PD-1-positive T cells in the peripheral blood of melanoma patients receiving PD-1 inhibitors is feasible. Furthermore, the tumor-antigen specificities and TCR repertoires of the circulating and tumor-infiltrating CD8^+^PD-1^+^ cells appeared similar \[[@CR118]\].

Conclusions {#Sec17}
===========

The era of cancer immunotherapy has arrived. This major breakthrough in cancer treatment holds great promise for increasing cure rates for patients with various cancer types in multiple disease settings. Checkpoint blockade antibodies targeting CTLA-4, PD-1, and PD-L1 axis have demonstrated impressive and durable disease control and promising responses in patients with multiple tumor types. Despite these advances, only a subset of patients benefits from immune checkpoint blockade therapies, with some patients experiencing mechanism-based irAEs. Translational biomarker research is one way to overcome these limitations of therapy. Biomarkers play a critical role in understanding potential mechanisms of action in patients, identifying patients who are likely to respond to the growing list of cancer therapeutics and avoiding the irAEs. Several *tumor-derived biomarkers* have been reported from recent correlative studies including PD-L1 expression on tumor cells, high tumor mutational load, and neoantigens. In addition, several *immune cell-derived biomarkers* showed better correlation with the clinical outcomes. The presence of TILs in tumor microenvironments, increased PD-L1 expression on immune cells, and the ratio of effector CD8^+^ T cells to FoxP3^+^ regulatory T cells in tumors are some examples of markers for clinical outcomes. Future studies are warranted to harmonize companion diagnostics (such as PD-L1 IHC) for accurate clinical assessment and application of the class of PD-1/PD-L1 inhibitors. It is of importance to further evaluate mutation load as a potential biomarker and develop effective tumor antigen-specific T cell assays to differentiate immunogenic neoepitopes from putative ones. The advances in translational immune biomarker research are essential for personalized cancer immunotherapy as either monotherapy or combinational therapy.
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